Title: 
Official Title: To ensure references to opioid overdose reversal agents in certain grant
            programs of the Department of Health and Human Services are not limited to
            naloxone.
Number of Sections: 2
Source: versions - Introduced in Senate
Media Type: text/xml

================================================================================

Section 1:
1.
            Short title
 This Act may be cited as the Halting the Epidemic of Addiction and Loss Act of 2025.

Section 2:
2.
            References to opioid overdose reversal agents in HHS grant programs
            
                (a)
                In general
 The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for emergency treatment of a known or suspected opioid overdose.
            
            
                (b)
                Existing references
                
                    (1)
                    Update
 Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal drug that has been approved or otherwise authorized for use by the Food and Drug Administration.
                
                
                    (2)
                    References
 A reference described in this paragraph is any reference to an opioid overdose reversal drug (such as naloxone) in any regulation or guidance of the Department of Health and Human Services that—
                    
                        (A)
 was issued before the date of enactment of this Act; and   (B) is included in—
                        
                            (i)
 the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act (42 U.S.C. 290ee–3a) (commonly referred to as State Opioid Response Grants and Tribal Opioid Response Grants); or
                        
                        
                            (ii)
 the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act (42 U.S.C. 290bb–22).


================================================================================

Raw Text:
119 S2336 IS: Halting the Epidemic of Addiction and Loss Act of 2025
U.S. Senate
2025-07-17
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



        II
        119th CONGRESS
        1st Session
        S. 2336
        IN THE SENATE OF THE UNITED STATES
        
            July 17, 2025
            Mr. Cornyn (for himself and Ms. Hassan) introduced the following bill; which was
                read twice and referred to the Committee on
                    Health, Education, Labor, and Pensions
        
        A BILL
        To ensure references to opioid overdose reversal agents in certain grant
            programs of the Department of Health and Human Services are not limited to
            naloxone.
    
    
        
            1.
            Short title
 This Act may be cited as the Halting the Epidemic of Addiction and Loss Act of 2025.
        
        
            2.
            References to opioid overdose reversal agents in HHS grant programs
            
                (a)
                In general
 The Secretary of Health and Human Services shall ensure that, as appropriate, whenever the Department of Health and Human Services issues a regulation or guidance for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal drug (such as a reference to naloxone) is inclusive of any opioid overdose reversal drug that has been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for emergency treatment of a known or suspected opioid overdose.
            
            
                (b)
                Existing references
                
                    (1)
                    Update
 Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal drug that has been approved or otherwise authorized for use by the Food and Drug Administration.
                
                
                    (2)
                    References
 A reference described in this paragraph is any reference to an opioid overdose reversal drug (such as naloxone) in any regulation or guidance of the Department of Health and Human Services that—
                    
                        (A)
 was issued before the date of enactment of this Act; and   (B) is included in—
                        
                            (i)
 the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act (42 U.S.C. 290ee–3a) (commonly referred to as State Opioid Response Grants and Tribal Opioid Response Grants); or
                        
                        
                            (ii)
 the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act (42 U.S.C. 290bb–22).